Business Wire

DENTAL-MONITORING

24.3.2020 18:50:12 CET | Business Wire | Press release

Share
SmileMate Virtual Consultation – Free Until 31st May

Dental Monitoring announced last week the launch of a simplified version of SmileMate Virtual Consultation - its tele dentistry solution to allow dental professionals to assess their new patient enquiries remotely and in a HIPAA compliant manner.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200324005658/en/

Given the scale of the pandemic, and the increasing containment measures taken by governments worldwide, tele dentistry such as SmileMate Virtual Consultation has emerged as a solution to help assess patients remotely in these unprecedented times - initiating a first consultation from home and preventing the spread of COVID-19.

Standing alongside all dental professionals, Dental Monitoring has now decided to provide until the end of May 2020, free access for SmileMate Virtual Consultation to all individual dentists and orthodontists worldwide.

SmileMate Virtual Consultation is a “light” version of SmileMate, simpler and more immediate to implement for these times - enabling rapid on-boarding and roll-out. It has been developed to allow practices to remotely assess their new patients directly through their website.

CEO and Co-founder of Dental Monitoring, Philippe Salah, explained: “Allowing free access to our solution until the end of May is our duty as global citizens. It is important that we help dental professionals find solutions so they can keep providing their expert care, even during the pandemic .”

On the accelerated development of SmileMate Virtual Consultation, CEO and Founder of SmileMate, Nick Duncan said: “I think I speak for the entire dental industry when I say that our sole focus at this time is to do whatever we can to help clinics get through the current period of uncertainty. We've worked hard to develop a new version of our technology that is easier to implement for both patients and individual clinics. As a partner of dental professionals, making it free for all independent dentists and orthodontists was the right thing to do.”

Dental Monitoring is working with dental professionals, to improve its solutions and help patients access dental care anytime, anywhere.

About SmileMate Virtual Consultation , remote assessment of new patients.
All new patient calls can be pre-qualified remotely using the SmileMate Virtual Consultation assessment tool directly through the doctor’s practice website. The process is simple:

Step 1 - The doctor simply installs a widget on its practice website. The new patient clicks on the widget, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an App or use a ScanBox and cheek retractors)

Step 2 - A comprehensive customized report is automatically generated by our AI engine and sent to the doctor

Step 3 - The doctor qualifies the patient’s needs on their SmileMate portal

Step 4 - The doctor reviews and personalizes the report before sharing with the patient together with their treatment options and a booking link if an appointment is required.

To implement SmileMate Virtual Consultation, please visit: https://dental-monitoring.com/maintain-patient-care/

After May 31st, 2020, and until the end of the pandemic, SmileMate Virtual Consultation will be available at a reduced 50% cost: US$150/month.

About Fast-Track Accelerated On-Boarding
SmileMate Virtual Consultation is ready for use in minutes after doctors and their teams have performed our free fast-track accelerated onboarding - a new simplified and streamlined implementation process, which is done 100% remotely through webinars and individual support by our customer support team.

To book a time slot for our next training session, please visit: https://dental-monitoring.com/maintain-patient-care/

About Dental Monitoring (www.dental-monitoring.com )
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company addressing the dental market. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the dental professionals, and after treatment to ensure the stability of the treatment outcome. The company operates in Europe, the United States and Asia-Pacific. It employs around 250 employees across its five offices located in Paris, Austin, London, Hong Kong and Sydney. SmileMate is a subsidiary of Dental Monitoring (https://www.smilemate.com/ ).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye